Intervention: Pazopanib Hydrochloride
Trial phase: Phase 2
SMILES: Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

computed tomography : Correlative studies

pharmacological study : Correlative studies

pazopanib hydrochloride : Given PO
Eligibility criteria:
Inclusion Criteria:

Histologically or cytologically confirmed nasopharyngeal carcinoma, meeting the following criteria:

World Health Organization (WHO) type II-III disease
Stage IV or recurrent disease
Must have failed at least 1 prior line of chemotherapy for metastatic or recurrent disease
Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan
No known brain metastases
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 or Karnofsky PS 70-100%
Life expectancy > 3 months
WBC >= 3,000/mm³
Absolute neutrophil count >= 1,500/mm³
Platelet count >= 100,000/mm³
Bilirubin normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (ULN)
Creatinine normal OR creatinine clearance >= 60 mL/min
Proteinuria =< 1+ on 2 consecutive dipsticks taken >= 1 week apart
Prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time (PTT) =< 1.2 times ULN

Systolic blood pressure (BP) =< 140 mm Hg and diastolic BP =< 90 mm Hg

Initiation or adjustment of BP medication allowed provided the average of 3 BP readings are < 140/90 mm Hg prior to study entry
No history of allergic reaction attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or to other study agents
No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
No cerebrovascular accident within the past 6 months

No history of any of the following diseases within the past 12 weeks:

Myocardial infarction
Cardiac arrhythmia
Admission for unstable angina
Cardiac angioplasty or stenting
Venous thrombosis

No New York Heart Association (NYHA) class III-IV heart failure

Patients with a history of NYHA class II heart failure are eligible provided they are asymptomatic on treatment
No significant electrocardiogram (ECG) abnormalities, including QTc prolongation (i.e., QTc >= 500 msec)
No serious or non-healing wound, ulcer, or bone fracture

No condition that would impair the ability to swallow and retain pazopanib hydrochloride, including any of the following:

Gastrointestinal tract disease resulting in an inability to take oral medication
Requirement for IV alimentation
Prior surgical procedures affecting absorption
Active peptic ulcer disease

No concurrent uncontrolled illness including, but not limited to, the following:

Coagulopathy
Ongoing or active infection
Psychiatric illness or social situation that would preclude study compliance
No known allergy to CT contrast agents
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
More than 4 weeks since prior radiotherapy
At least 4 weeks since prior surgery
No prior antiangiogenesis therapy
No other concurrent investigational agents
No other concurrent anticancer therapy
No concurrent medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of pazopanib hydrochloride, as determined by the Principal Investigator
No concurrent medications that have the potential to interact with the cytochrome P450 (CYP) isoenzymes CYP2C9 and CYP3A4

No concurrent therapeutic warfarin

Low molecular weight heparin or prophylactic low-dose warfarin allowed
No concurrent antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients